Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARBLI vs ANSPOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Spasticity due to multiple sclerosis,Spinal cord injury,Alcohol use disorder (off-label)
FDA-approved: Treatment of respiratory tract infections, otitis media, skin and skin structure infections, bone infections, genitourinary tract infections caused by susceptible bacteria.,Off-label: Prosthetic joint infections, dental infections, endocarditis prophylaxis.
10 mg orally once daily.
250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
1.5–2 hours in adults with normal renal function; prolonged to 20–30 hours in severe renal impairment (Cr Cl <10 m L/min)
Primarily hydrolyzed by esterases to baclofen; baclofen is minimally metabolized (mainly renal clearance of unchanged drug).
Cephalexin is not extensively metabolized; it is primarily excreted unchanged in the urine. Minor hepatic metabolism may occur.
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Primarily renal (90–95%) as unchanged drug via glomerular filtration and tubular secretion; biliary excretion negligible (<1%)
>99% bound to albumin and alpha-1-acid glycoprotein.
10–20% bound to serum albumin
0.7 L/kg, indicating extensive tissue distribution.
0.13–0.22 L/kg; indicates distribution primarily into extracellular fluid
Oral: 70% (range 60-80%); IV: 100%.
Oral: 75–90% (well absorbed); IM: 100%
e GFR ≥30 m L/min/1.73 m²: no adjustment. e GFR <30 m L/min/1.73 m²: use not recommended.
Cr Cl 10-50 m L/min: 250 mg every 12-24 hours. Cr Cl <10 m L/min: 250 mg every 24-48 hours.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended.
No specific adjustment recommended; monitor for adverse effects in severe impairment.
Not established for patients <18 years.
12.5-25 mg/kg orally every 6 hours; maximum 50 mg/kg/day.
No specific dose adjustment required; monitor renal function.
Start at lower end of dosing range; monitor renal function and adjust based on Cr Cl.
Abrupt discontinuation may precipitate withdrawal reactions including seizures, hallucinations, and life-threatening hyperthermia (similar to baclofen withdrawal).
No FDA boxed warning exists for cephalexin.
Risk of withdrawal symptoms with abrupt cessation,May cause sedation and dizziness,Use caution in renal impairment,May exacerbate psychiatric disorders,Avoid with alcohol or CNS depressants
Hypersensitivity reactions including anaphylaxis.,Clostridioides difficile-associated diarrhea (CDAD).,Dosage adjustment required in renal impairment.,Seizures with high doses or renal failure.,Potential for superinfection with prolonged use.
Hypersensitivity to baclofen or any component of the formulation
Known hypersensitivity to cephalosporins or penicillins (cross-sensitivity).,Previous immediate hypersensitivity reaction to penicillins.
Avoid alcohol. No specific food interactions reported, but take with or without food consistently to maintain stable drug levels.
Iron-fortified infant formula and iron supplements may reduce absorption; take at least 2 hours apart. No other significant food interactions. Avoid alcohol.
ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at doses up to 4 times the maximum recommended human dose based on body surface area. However, fetal toxicity (reduced fetal weight, delayed ossification) occurred at maternally toxic doses. Based on mechanism (GABAB agonist), potential risk cannot be excluded. First trimester: unknown risk; second/third trimester: possible risk of fetal harm from maternal muscle relaxation; third trimester: risk of neonatal withdrawal (hypotonia, respiratory depression) if used near term.
Cefradine (ANSPOR) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and adequate well-controlled studies in pregnant women are lacking. No evidence of teratogenicity; however, caution is advised. First trimester: no known risk; second and third trimesters: no known fetal adverse effects.
No data on excretion in human milk. Arbaclofen is a small molecule (MW 215.68) and likely excreted into breast milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., sedation, respiratory depression) in nursing infants, breastfeeding is not recommended during therapy.
Cefradine is excreted into human breast milk in low concentrations. M/P ratio is approximately 0.12–0.20. Considered compatible with breastfeeding by the American Academy of Pediatrics; however, monitor infant for potential diarrhea or allergic reaction.
No specific dosing guidelines established for pregnancy due to lack of data. Pregnancy may alter pharmacokinetics (increased volume of distribution, renal clearance) potentially requiring dose adjustments; however, no recommendations can be made because drug is contraindicated in pregnancy.
Increased renal clearance during pregnancy may lower serum concentrations of cefradine. Standard dosing (250–500 mg every 6 hours) is generally adequate; however, for severe infections, consider higher doses or more frequent administration based on clinical response. No specific dose adjustment is routinely recommended, but monitoring therapeutic efficacy is advised.
ARBLI (arbaclofen) is a prodrug of baclofen used for spasticity. Titrate slowly to avoid CNS depression. Monitor renal function; dose adjustment required in Cr Cl <60 m L/min. Avoid abrupt discontinuation due to withdrawal symptoms. Use with caution in patients with history of substance abuse due to abuse potential.
ANSPOR (cefdinir) is a third-generation oral cephalosporin with activity against Gram-positive and Gram-negative bacteria. It is stable in the presence of some beta-lactamases. Dose adjustment required for Cr Cl <30 m L/min. Avoid use in patients with immediate hypersensitivity to penicillins due to cross-reactivity (approx 10%). Administer with iron supplements or iron-fortified infant formula at least 2 hours apart to reduce chelation. Suspension should be refrigerated and discarded after 10 days.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Do not stop taking abruptly; gradual dose reduction is necessary to prevent withdrawal symptoms (hallucinations, seizures, rapid heart rate).,Avoid driving or operating heavy machinery until you know how ARBLI affects you, as it may cause dizziness or drowsiness.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation risk.,Inform your doctor if you have kidney problems, diabetes, or a history of substance abuse.,Store at room temperature away from moisture and heat.
Take exactly as prescribed, even if you feel better.,Complete the full course of therapy.,If using suspension, shake well before each dose. Refrigerate and discard after 10 days.,Avoid alcohol while taking this medication.,Notify your doctor if you experience diarrhea, rash, or signs of allergic reaction.,Take iron supplements or iron-fortified infant formula at least 2 hours apart from ANSPOR.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARBLI vs ANSPOR, answered by our medical review team.
ARBLI is a Cephalosporin Antibiotic that works by ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.. ANSPOR is a Cephalosporin Antibiotic that works by Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARBLI and ANSPOR depend on the specific clinical indication. These are both Cephalosporin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARBLI is: 10 mg orally once daily.. The standard adult dose of ANSPOR is: 250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARBLI and ANSPOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARBLI is classified as Category C. ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at d. ANSPOR is classified as Category C. Cefradine (ANSPOR) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and adequate well-controlled studies in pregnant women are lacking. N. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.